文献速递慢性肾脏病

慢性肾脏病患者处方质量指标的开发与初步验证

Development and initial validation of prescribing quality indicators for patients with chronic kidney disease.
PubMed 文献 · Nephrol Dial Transplant · 2016-01-06

本研究基于临床实践指南并采用RAND/UCLA适宜性方法,由12位专家评估,最终形成16项慢性肾脏病处方质量指标(PQI),覆盖高血压、白蛋白尿、矿物质与骨异常、他汀处方及潜在不安全用药。该指标集在包含超过4500例糖尿病合并慢性肾脏病患者的荷兰初级保健数据库中成功应用,部分指标因合格患者数过少而无法可靠计算,结果提示该人群治疗质量仍有提升空间。

要点

  • 最终形成16项慢性肾脏病处方质量指标,经专家小组认可具有内容效度和表面效度。
  • 指标覆盖高血压、白蛋白尿、矿物质与骨异常、他汀处方及潜在不安全用药。
  • 在荷兰初级保健数据库应用中,部分指标因合格患者数过少而无法可靠计算。

核心结论

  • 开发了16项用于衡量慢性肾脏病患者治疗质量的处方质量指标,具有足够的内容效度和表面效度以及操作可行性,可用于指出需要改进的优先领域。

研究设计与样本

  • 基于临床实践指南形成候选指标,采用RAND/UCLA适宜性方法由12位专家评估有效性,并在包含超过4500例糖尿病合并慢性肾脏病患者的荷兰初级保健数据库中测试可行性。

主要发现

  • 初始22项处方质量指标经12位专家评估,修改10项、新增2项、拒绝8项后,最终16项被专家小组接受为有效。
  • 这些指标聚焦于高血压、白蛋白尿、矿物质与骨异常、他汀处方及潜在不安全用药的治疗。
  • 指标在初级保健数据库中成功应用于测量治疗质量,但部分指标因合格患者数过少而无法可靠计算。
  • 结果显示该人群治疗质量仍有提升空间。

关键数值与推荐

  • 最终处方质量指标共16项,覆盖高血压、白蛋白尿、矿物质与骨异常、他汀处方及潜在不安全用药。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 部分指标因合格患者数过少而无法可靠计算。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Quality assessment is a key element for improving the quality of care. Currently, a comprehensive indicator set for measuring the quality of medication treatment in patients with chronic kidney disease (CKD) is lacking. Our aim was to develop and validate a set of prescribing quality indicators (PQIs) for CKD care, and to test the feasibility of applying this set in practice. METHODS: Potential indicators were based on clinical practice guidelines and evaluated using the RAND/UCLA Appropriateness Method. This is a structured process in which an expert panel assesses the validity of the indicators. Feasibility was tested in a Dutch primary care database including >4500 diabetes patients with CKD. RESULTS: An initial list of 22 PQIs was assessed by 12 experts. After changing 10 PQIs, adding 2 and rejecting 8, a final list of 16 indicators was accepted by the expert panel as valid. These PQIs focused on the treatment of hypertension, albuminuria, mineral and bone disorder, statin prescribing and possible unsafe medication. The indicators were successfully applied to measure treatment quality in the primary care database, but for some indicators the number of eligible patients was too small for reliable calculation. Results showed that there was room for improvement in the treatment quality of this population. CONCLUSIONS: We developed a set of 16 PQIs for measuring the quality of treatment in CKD patients, which had sufficient content and face validity as well as operational feasibility. These PQIs can be used to point out priority areas for improvement.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Smits KP, Sidorenkov G, Bilo HJ, et al. Development and initial validation of prescribing quality indicators for patients with chronic kidney disease. Nephrol Dial Transplant. 2016. PMID: 26743176

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。